Hepatitis C virus (HCV) infection has a high prevalence in people who inject drugs in Europe, although HCV infection is both preventable and curable. Effective interventions that target the prevention of HCV transmission and the treatment of hepatitis C are needed, particularly for so-called ‘hard to reach’ and vulnerable populations.
Preventing hepatitis C infection remains one of the major challenges for Europe’s public health responses to drug injecting. This publication, with contributions from leading international experts, provides a state-of-the-art review of the epidemiology of HCV infection in Europe and its estimated prevalence among people who inject drugs. The new medicines and treatment regimens driving the transformation in the HCV treatment landscape are reviewed in detail.